Skip Navigation
Print This Page
Share this page: More

Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis

Application No: NA_00072395

Principal Investigator: Daniel Harrison

For more information please contact Daniel Harrison at 443-287-0400

This research is being conducted to determine if a medicine called AVP-923 (Dextromethorphan/Quinidine) is safe and effective at reducing symptoms of central neuropathic pain due to multiple sclerosis. Neuropathic pain is often experienced as chronic pain in the extremities, and is usually not responsive to standard pain relief medications.   AVP-923 is currently FDA-approved for use in patients with pseudobulbar affect, and is taken as an oral medication. 

Participants must be between the ages of 18 and 85, experience neuropathic pain, and have a diagnosis of multiple sclerosis.  Participants will be randomly assigned to receive either one of 3 doses of the study drug or a matching placebo, which will be taken twice daily as an oral medication for an 85 day study period.  The success or failure of pain control will be assessed by self-assessment tools.


© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer